BioPharma Dive4m
Atea plans Phase 3 study for hepatitis C drug after mid-stage results
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...
BioPharma Dive33m
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...